GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2013

Novartis Opens First Biomanufacturing Facility in Asia

  • Novartis has opened its first biopharmaceuticals manufacturing plant in Asia. The facility, based in Singapore, will conduct commercial and clinical scale manufacturing and engage in process development (PD capabilities).

    Last October, Novartis reported the construction of the new cell culture production site in Singapore with an investment valued at over $500 million. It is co-located with the pharmaceutical production site based in Tuas, Singapore.

    “This investment further strengthens our strategy to establish key strategic sites based on technological competencies. Singapore will be strengthened through a new facility for biotechnology, which is a growing segment of our business,” Novartis’s CEO Joseph Jimenez said at the time of the October announcement. “We have chosen Singapore as strategic supply point as it offers a wide range of advantages due to its strong local biomedical presence and knowledge, skilled labor as well as proximity to growth markets in Asia.”

    Novartis has several operations in Singapore including the Novartis Institute for Tropical Diseases (NITD), the Novartis Asia-Pacific head offices, and two production facilities for Alcon as well as one pharmaceutical manufacturing site.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »